Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 短暫停牌 茲提述中基長壽科學集團有限公司（「本公司」）日期為二零二五年六月十五日的公告 （「該公告」），內容有關根據一般授權認購新股份。除非文義另有所指，本公告所用 詞彙與該公告所界定者具有相同涵義。 應本公司要求，本公司股份在二零二五年六月十六日（星期一）上午九時正起於香港 聯合交易所有限公司的交易短暫停牌，以待刊發有關終止認購本公司新股份公告。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 閆立 香港，二零二五年六月十六日 – 1 – 於本公告日期，董事如下： | 執行董事 | 獨立非執行董事 | 閆立先生 | 李思先生 | （主席） | | --- | --- | --- | --- | --- | | 閆一帆先生 | 黃江先生 | （行政總裁） | 李小雙先生 | 黃慈 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 根據一般授權認購新股份 於二零二五年六月十五日（星期日），本公司與認購人訂立認購協議，據此，認購 人已有條件地同意認購，而本公司已有條件地同意配發及發行合共92,855,806股 認購股份，價格為每股認購股份0.33港元。認購事項須待下文「認購事項的先決條 件」所載的各項條件達成後方可作實。 認購協議 日期 假設於本公告日期至完成日期之間本公司已發行股本概無變動，則認購股份相當 於本公司於本公告日期現有已發行股本的約16.99%，並相當於本公司經配發及 發 行 認 購 股 份 擴 大 後（須 待 認 購 事 項 完 成 後 方 可 作 實）的 已 發 行 股 本 的 約 14.52%。 認購價較： – 1 – (1) 股份於截至二零二五年六月十 ...

Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ) ( 於百慕達註冊成立之有限公司 (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Non-registered holders(Note 1) 28 April 2025 Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Annual Report 2024 and Circular of Annual General Meeting (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese langu ...

中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Registered Shareholders, 28 April 2025 Zhong Ji Longevity Science Group Limited Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Annual Report 2024, Circular and Proxy Form of Annual General Meeting (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese ...

此 乃 要 件 請 即 處 理 閣下如對本通函任何方面或應採取之行動有疑問，應諮詢持牌證券交易商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已將名下全部中基長壽科學集團有限公司股份售出或轉讓，應立即將本通函及隨附之代表委 任表格送交買主或承讓人，或經手買賣或轉讓之銀行、持牌證券交易商或其他代理商，以便轉交買主 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本公司謹訂於二零二五年六月二十七日（星期五）上午十時三十分假座香港九龍灣臨澤街8號啟匯30樓 舉行股東周年大會，召開大會之通告載於本通函第14至18頁。 無論 閣下能否出席大會，務請按照隨附代表委任表格上印備之指示將表格填妥，並盡快及無論如 何最遲於大會或其任何續會舉行時間48小時前，交回本公司之香港股份過戶登記分處香港中央證券 登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓。填妥及交回代表委任表格 後， 閣下仍可依願親身出席大會或其任何續會，並於會上表決。 Z ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本通告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited （於百慕達註冊成立之有限公司） 中基長壽科學集團有限公司 （股份代號：767） 股東周年大會通告 「有關期間」指由本決議案通過當日起至下列最早時限止期間： (a) 本公司下屆股東周年大會結束； – 2 – 4. 作為特別事項，考慮並酌情以普通決議案方式通過以下決議案： (A)「動議： (i) 在本決議案(iii)分段之規限下，一般及無條件批准董事於有關期間（定 義見下文）內，按照所有適用法例及本公司之經修訂及經重列的公司細 則並在其規限下行使本公司一切權力，以配發、發行及處理本公司股 本中每股面值0.01港元之額外股份，並作出或授出將要或可能須行使有 關權力之要約、協議及購股權（包括可轉換為本公司股份之認股權證、 債券及債權證）； (ii) 本決議案(i)分段所述之批准，將授權董事於有關期間內作出或授出將 要或可能須於有 ...

一致性：本報告在適合的情況下對公開範圍和計算方法發生變化的數據進行描述。 報告語言 本報告以繁體中文及英文版本發佈。本報告內容如有任何歧義，以中文版為準。本報告的電子版可通過聯交所網站進 行閱讀和下載。 1. 關於本報告 中基長壽科學集團有限公司（下稱「本公司」）及其附屬公司（下稱「本集團」或「我們」）已按照香港聯合交易所有限公司 （「聯交所」）《證券上市規則》附錄C2 —《環境、社會及管治報告指引》（下稱「《指引》」）的披露責任編製環境、社會及管 治（下稱「環境、社會及管治」）報告（下稱「本報告」）。本報告總結二零二四年一月一日至二零二四年十二月三十一日 止年度（下稱「二零二四年度」或「報告期」）有關本集團環境、社會及管治方面的行動及量化表現，亦是與持份者建立 及保持良好關係的溝通管道之一。有關管治方面的資訊，可透過本集團二零二四年度年報中的「企業管治報告」章節了 解。 報告範圍 本集團管理層根據重要性原則對報告範圍進行討論、識別及確認，並考慮核心業務及主要收益來源。由於本集團的主 要的營運據點為本集團的香港辦公室，其運作對本集團在環境方面的關鍵績效指標（「關鍵績效指標」）有重大影響，因 此本報告中的環境方 ...

Financial Performance - For the year ended December 31, 2024, the revenue was HK$166,181,000, a significant increase of 156% compared to HK$64,989,000 in 2023[15]. - The loss attributable to the owners of the Company for 2024 was HK$34,726,000, compared to a profit of HK$2,313,000 in 2023[15]. - As of December 31, 2024, total shareholders' equity was HK$400,139,000, down from HK$430,465,000 in 2023, representing a decrease of approximately 7%[18]. - The Group recorded total revenue of approximately HK$166.2 million for FY2024, a significant increase from HK$65.0 million in FY2023, while incurring a loss of approximately HK$34.8 million compared to a profit of HK$2.5 million in the previous year[53]. - The basic and diluted loss per share for FY2024 was approximately HK$4.15 cents, compared to earnings per share of HK$0.15 cents in FY2023[54]. - As of December 31, 2024, the consolidated net assets of the Group were approximately HK$400.1 million, a decrease from HK$430.5 million in FY2023[54]. - The Group's cash and cash equivalents decreased to approximately HK$47,842,000 as of December 31, 2024, down from HK$81,075,000 as of December 31, 2023[99]. - The Group's gearing ratio as of December 31, 2024, was approximately 2.9%, an increase from 2.1% as of December 31, 2023[165]. Longevity Science Business - The Company is focused on becoming a world-leading platform for global cellular medical sciences across the entire industry chain[20]. - The Company aims to optimize resource allocation and strengthen core competitiveness in the longevity science business[20]. - The Company has made steady progress in advancing its strategic plans amid a recovering global economy[20]. - The Chairman emphasized the commitment to establishing a world-leading platform for the transformation and application of longevity science[20]. - In 2024, the longevity biological products segment achieved significant sales revenue growth, driven by optimized research, development, and production processes, as well as market expansion through joint ventures and mergers[22][25]. - The longevity management sector has enhanced service quality and established longevity management centers in major cities, with early successes noted in Hong Kong and Shenzhen, contributing to the brand's growing influence in high-quality health services[23][25]. - The longevity science business contributed approximately HK$142.0 million in revenue for FY2024, but reported a segment loss of approximately HK$17.6 million[53]. - The revenue from the longevity science segment amounted to approximately HK$142,016,000 for FY2024, a significant increase from HK$31,326,000 in FY2023[77]. - Approximately HK$39,605,000 of the revenue in the longevity science segment was generated from diagnostic consultation and medical testing, while HK$102,411,000 was from sales of longevity biological products[77]. - The segment incurred a loss of approximately HK$17,559,000 in FY2024, an improvement from a loss of HK$24,016,000 in FY2023, indicating a positive trend despite ongoing challenges[81]. Money Lending and Financial Advisory Business - The money lending and financial advisory business is recovering steadily, although market constraints on secured home loans persist due to subdued property transactions in the PRC[35]. - The money lending and financial advisory business generated static revenue of approximately HK$24.2 million in FY2024, down from HK$33.7 million in FY2023, but increased segment profit to approximately HK$34.4 million from HK$25.4 million[58]. - The Group's strategic partners in the money lending business include FOTIC, Fanhua, and Haier, with ongoing negotiations to monetize portions of the loan portfolio[61]. - The average loan size for first mortgages under FOTIC and ShanXi was approximately RMB0.86 million, with interest rates ranging from 8.4% to 19.2% for FY2024[120][124]. - The average loan size for first and second mortgages under Fanhua and Haier was approximately RMB0.2 million, with interest rates ranging from 12% to 18% for FY2024[124]. - The Group's strategic partners loan assets were accounted as other receivables for approximately HK$172,917,000 before impairments as of December 31, 2024[127]. - The top five borrowers accounted for approximately 89.19% of the total loan and interest receivables of the Group as of December 31, 2024, an increase from 79.93% in 2023[134]. - The Group is required to maintain a risk provision top-up fund equivalent to 20-30% of the initial loan principals borrowed by customers referred to Fanhua and Haier[117]. - The Group earns various fees including loan origination fees, management service fees, recovery fees, and accrued interest income from strategic partners[119]. Operational Challenges and Strategic Initiatives - The Company faced operational challenges due to a license revocation by the Hong Kong Department of Health, resulting in the loss of past rental expenses and capital expenditures[47]. - The Company has restructured its operations and restored business partnerships following a police investigation into former employees, which was confirmed to be unrelated to the company itself[36]. - The Group is focusing on expanding its longevity science business through membership programs and distribution channels, targeting anti-cancer, anti-aging, and knee joint health products[50]. - The Group's approach to the money lending business has been prudent due to a sluggish sentiment in the PRC property market, resulting in a static performance[52]. - The Group plans to continue monitoring market conditions to seek suitable tenants for stable rental income or consider disposing of investment properties for capital appreciation[86]. - The Group has initiated recovery actions on previously impaired loans, indicating a proactive approach to asset management[134]. Corporate Governance and Management - The Company has a diverse board with members holding significant experience in innovation, finance, and corporate governance, enhancing strategic decision-making capabilities[195][196][197][200]. - The board's composition includes professionals with backgrounds in healthcare, investment, and media, indicating a multifaceted approach to market expansion and product development[195][196][200]. - The Company is focused on leveraging the expertise of its directors to drive growth and explore new market opportunities[195][196][197][200]. - The presence of directors with international experience suggests potential for global partnerships and collaborations in future projects[195][196][200]. - The board's commitment to risk management and governance is reflected in the establishment of various committees, including audit and remuneration[197][199]. Future Outlook and Strategic Plans - Looking ahead to 2025, the company aims to become the "Global Leader in Longevity Science," focusing on technology leadership, innovation-driven growth, and global expansion while increasing investment in research and development[28][31]. - The company plans to integrate AI with longevity technology by establishing an AI longevity technology joint laboratory, aiming for early disease prediction and personalized health management solutions[29][31]. - The Group plans to operate under a light asset model to reduce operational pressure and risk while expanding its longevity science business through potential joint ventures[177]. - The company aims to enhance its position in the longevity science and biomedical sectors through strategic investments and expansions[182][183].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 另茲提述本公司日期為二零二三年十二月十一日之澄清公告（「澄清公告」），內容有 關（其中包括）日期為二零二三年十二月九日的若干媒體報導，指衛生署（「衛生署」） 轄下私營醫療機構規管辦公室（「規管辦公室」）以規管辦公室對本公司提出的指控為 由，吊銷中基長壽科學集團有限公司的日間醫療中心牌照（「日間醫療中心牌照」）， 自二零二三年十二月九日起生效，有關指控如下： (i) 管有及涉嫌使用無牌X光機；及 (ii) 本公司日間醫療中心處理涉嫌未經註冊之藥劑製品； (iii) 妨礙或阻延衞生署獲授權人員執行其職能。 – 1 – Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 內幕消息 衛生署對本公司轄下中基長壽日間醫療中心處理之 最新進展 本公告由中基長壽科學集團有限公司（「本公司」）董事（「董事」）會 ...

成立合资公司符合本集团的长寿科学业务发展策略及计划，将有利于本集团未来的业务发展。合资公司 将打造全球领先的生命科学产业赋能平台，构建"学术会议、技术转化、产业落地"位一体生态链，推动 中国生命科学领域产学研深度融合。董事会相信合资协议进一步完善本集团在长寿科学诊断及医疗服务 领域的布局，为本公司开拓新的长寿科学收入来源，以期长远为本集团带来更加稳定及持续增长的收 入。 本集团主要透过其附属公司中基健康从事提供健康长寿管理服务及健康长寿产品的生产和销售。董事会 认为健康长寿科学市场的前景广阔，因为观察到全球的富裕客户更愿意接受及花费在长寿科学应用上， 以提升彼等的整体健康及免疫状况，并促进彼等身体年轻化。 智通财经APP讯，中基长寿科学(00767)发布公告，于2025年4月1日，本公司的全资附属公司深圳市中基 健康科学有限公司(中基健康)与华骊(广东)生命科学技术有限公司(华骊生命)签订有关于中国成立一间合 资公司的合资协议(合资协议)，合资公司于成立时将由中基健康拥有51%及华骊生命拥有49%的股权。 合资公司将主要从事于中国提供长寿健康服务。 合资公司的初始注册资本为人民币100万元，将由中基健康及华骊 ...